L-
asparaginase is an important drug in the treatment of childhood acute lymphoblastic leukaemia (ALL). Treatment is associated with several toxicities, including
acute pancreatitis.
Clinical course, presentation, re-exposure to L-asparginase after
pancreatitis and risk of recurrent
pancreatitis within an
asparaginase-intensive protocol has been poorly reported. Children (1-17 years) on the ongoing Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 protocol with
asparaginase-associated
pancreatitis (
AAP) diagnosed between 2008 and 2012 were identified through the online NOPHO ALL toxicity registry. NOPHO ALL2008 includes eight or 15 doses of intramuscular pegylated L-asparginase (
PEG-asparaginase) 1000 iu/m(2) /dose at 2-6 weeks intervals, with a total of 30 weeks of exposure to
PEG-asparaginase (clinicaltrials.gov no: NCT00819351). Of 786 children, 45 were diagnosed with
AAP with a cumulative risk of
AAP of 5·9%.
AAP occurred after a median of five doses (range 1-13), and 11 d (median) from the latest administration of
PEG-Asparaginase. Thirteen patients developed pseudocysts (30%) and 11 patients developed
necrosis (25%). One patient died from
pancreatitis. Twelve
AAP patients were re-exposed to L-asparginase, two of whom developed mild
AAP once more, after four and six doses respectively. In conclusion, re-exposure to
PEG-asparaginase in ALL patients with mild
AAP seems safe.